Health Affairs September 24, 2021
A recent Health Affairs blog post on the more than two-decade history of Gilead’s HIV medications misrepresented Gilead’s long-established, patient-driven approach to research and development of HIV therapies. The authors suggest that Gilead “delay[ed] access to safer medications in the name of profit.” This is simply wrong. They ascribe greed to a process that has been driven only by patients’ needs and the urgency of our task. And they discount the difficult decisions with imperfect information that companies frequently must make about how and where to invest limited resources.
In fact, Gilead’s efforts to advance HIV therapy over more than two decades represent the iterative scientific process and incremental progress that are fundamental to the most innovative drug development work...
Today's Sponsors
Today's Sponsor